Prokidney (PROK) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Prokidney in October 2026.
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Prokidney (PROK) Stock Forecast
Analyst price target, next 12 months
$5.39
+282.2% vs today's $1.41
Price range over the last 12 months
Close to its 12-month low
Analysts covering Prokidney have a consensus 12-month target of $5.39, above the current price of $1.41.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 19 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying ProKidney's stock, which has significant growth potential according to their targets.
Financial Health
ProKidney Corp is generating modest revenue and cash flow, indicating stable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
